371 related articles for article (PubMed ID: 8744073)
21. Torsades de pointes during low-dosage sotalol therapy in haemodialysis patients.
Huynh-Do U; Wahl C; Sulzer M; Bühler H; Keusch G
Nephrol Dial Transplant; 1996 Jun; 11(6):1153-4. PubMed ID: 8671988
[No Abstract] [Full Text] [Related]
22. Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride.
Ohashi J; Yasuda S; Miyazaki S; Shimizu W; Morii I; Kurita T; Kawamura A; Kamakura S; Nonogi H
J Cardiovasc Pharmacol; 2006 Dec; 48(6):274-9. PubMed ID: 17204905
[TBL] [Abstract][Full Text] [Related]
23. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
[TBL] [Abstract][Full Text] [Related]
24. Sotalol: An important new antiarrhythmic.
Anderson JL; Prystowsky EN
Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
[TBL] [Abstract][Full Text] [Related]
25. Experimental study on the mechanism of sex difference in the risk of torsade de pointes.
Ruan YF; Liu N; Zhou Q; Li Y; Wang L
Chin Med J (Engl); 2004 Apr; 117(4):538-41. PubMed ID: 15109445
[TBL] [Abstract][Full Text] [Related]
26. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
27. [Ventricular pro-arrhythmic effects of anti-arrhythmia drugs].
Jaillon P; Simon T
Therapie; 1992; 47(3):187-92. PubMed ID: 1295119
[TBL] [Abstract][Full Text] [Related]
28. Multicenter Analysis of Dosing Protocols for Sotalol Initiation.
Biswas M; Levy A; Weber R; Tarakji K; Chung M; Noseworthy PA; Newton-Cheh C; Rosenberg MA
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):212-218. PubMed ID: 31707834
[TBL] [Abstract][Full Text] [Related]
29. Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate.
Sasse M; Paul T; Bergmann P; Kallfelz HC
Pacing Clin Electrophysiol; 1998 May; 21(5):1164-6. PubMed ID: 9604253
[TBL] [Abstract][Full Text] [Related]
30. [Torsade de pointes].
Haverkamp W; Hördt M; Chen X; Hindricks G; Willems S; Kottkamp H; Rotman B; Brunn J; Borggrefe M; Breithardt G
Z Kardiol; 1993 Dec; 82(12):763-74. PubMed ID: 8147050
[TBL] [Abstract][Full Text] [Related]
31. Amiodarone-associated "torsade de pointes". Relevance of concomitant cardiovascular medication in a patient with atrial fibrillation and structural heart disease.
Schrickel J; Bielik H; Yang A; Schwab JO; Shlevkov N; Schimpf R; Lüderitz B; Lewalter T
Z Kardiol; 2003 Oct; 92(10):889-92. PubMed ID: 14579055
[TBL] [Abstract][Full Text] [Related]
32. [Calmodulin antagonist inhibits torsade de pointes induced by d-sotalol in an isolated rabbit heart model].
Pu J; Zhang CT; Bai R; Liu N; Li Y; Wang L
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Apr; 33(4):364-8. PubMed ID: 15932674
[TBL] [Abstract][Full Text] [Related]
33. Torsades de pointes with administration of high-dose intravenous d-sotalol to a patient with congestive heart failure.
Gottlieb SS; Cines M; Marshall J
Pharmacotherapy; 1997; 17(4):830-1. PubMed ID: 9250567
[TBL] [Abstract][Full Text] [Related]
34. Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions.
Antonelli D; Atar S; Freedberg NA; Rosenfeld T
Isr Med Assoc J; 2005 Mar; 7(3):163-5. PubMed ID: 15792261
[TBL] [Abstract][Full Text] [Related]
35. Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes.
Farkas A; Leprán I; Papp JG
J Cardiovasc Pharmacol; 2002 Feb; 39(2):287-97. PubMed ID: 11791015
[TBL] [Abstract][Full Text] [Related]
36. Gender differences in cardiac repolarization following intravenous sotalol administration.
Somberg JC; Preston RA; Ranade V; Cvetanovic I; Molnar J
J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):86-92. PubMed ID: 21527783
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.
Ting C; Malloy R; Knowles D
J Cardiovasc Pharmacol Ther; 2020 Sep; 25(5):438-443. PubMed ID: 32347108
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
Pfammatter JP; Paul T; Lehmann C; Kallfelz HC
J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
[TBL] [Abstract][Full Text] [Related]
39. Sex difference in risk of torsade de pointes with d,l-sotalol.
Lehmann MH; Hardy S; Archibald D; quart B; MacNeil DJ
Circulation; 1996 Nov; 94(10):2535-41. PubMed ID: 8921798
[TBL] [Abstract][Full Text] [Related]
40. Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program.
Sugrue A; Kremen V; Qiang B; Sheldon SH; DeSimone CV; Sapir Y; Striemer BL; Brady P; Asirvatham SJ; Ackerman MJ; Friedman P; Noseworthy PA
Cardiovasc Drugs Ther; 2015; 29(5):433-41. PubMed ID: 26411977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
